Today's sales statistics of Snow Muscle Cream did not surprise Su Zhe too much.

Although the sales volume has increased a lot, the magnitude is not too large, of course, this is only compared to the previous increase rate of Sekkura.

If you compare the sales of snow cream with other cosmetics, the increase in snow cream is much faster.

It's just that now because of the production capacity problem of Yadai Group, even if the market demand for snow muscle cream is large, the sales volume cannot increase too much at once, after all, the production capacity is here.

If the production capacity of Sekka cream is only one million bottles a day, it is impossible to sell two million bottles a day, which is obviously impossible.

Therefore, the improvement of the snow muscle cream was completely expected by Su Zhe, so naturally there would not be much surprise.

After reading the sales statistics of Snow Muscle Cream, he opened another email, that is, an email from Li Changhua.

It turned out that the email sent by Li Changhua was the information of a large pharmaceutical factory, and it was for Su Zhe to make a reference, because Li Changhua was ready to let Changhua Pharmaceutical acquire this pharmaceutical factory to increase the production capacity of drugs.

As long as Su Zhe thinks that there is no problem, then this acquisition can start to act.

No wonder Li Changhua sent him an email 3, it was originally for the acquisition of the pharmaceutical factory, but with the more and more treatment potions provided by the drug delivery factory, Changhua Pharmaceutical's production capacity does need to be increased so that it can meet the production demand.

Otherwise, it would be a waste of so many healing potions, and if they can't be used, it will be the biggest waste.

Therefore, Li Changhua has been thinking of a way. to increase the production capacity of Changhua Pharmaceutical.

Recently, he has been looking for a suitable acquisition target. In the shortest possible time. It can improve the production capacity of Changhua Pharmaceutical.

And since Li Changhua will send the information of this pharmaceutical factory for Su Zhe's reference, it means that Li Changhua also feels that the conditions of this pharmaceutical factory meet the needs of Changhua Pharmaceutical's acquisition, so he will let him make a decision.

Su Zhe also knew that Changhua Pharmaceutical's increase in production capacity was indeed very urgent, and the shorter the time, the better, so he did this. Don't dare to be careless.

He immediately opened the attachment and began to check the information of the pharmaceutical factory so that he could make a decision so that Li Changhua could start arranging.

The pharmaceutical factory that Li Changhua fancies, called Qinhai Pharmaceutical Group, is a large-scale comprehensive modern pharmaceutical enterprise that covers an area of more than one million square meters and has more than 2,000 employees.

Qinhai Pharmaceutical Group has built a production base covering an area of one million square meters for preparation, biotechnology, chemical synthesis, antibiotic fermentation, etc., as well as a modern production workshop, and the production equipment has domestic equipment. and even the world's leading production capacity and production level.

It can produce 15,000 tons of APIs, 2 billion powder injections, 14 billion tablets, 10 billion capsules, 100 million water injections, and 100 million bottles of large-volume injections annually.

This is the information that Li Changhua went to the field to investigate, so it has a high degree of authenticity.

This Qinhai Pharmaceutical Group. Whether it is the area or the scale of production, it is much more than the previously acquired Xinjing Pharmaceutical.

Moreover, there is still a lot of room for improvement in the production capacity of Qinhai Pharmaceutical Group.

According to the number returned from the inspection by Li Changhua and other professionals, the production capacity of Qinhai Pharmaceutical Group can be increased by another 30 percent in a short period of time.

Even if the production capacity is not increased, the current production capacity of Qinhai Pharmaceutical Group is already very good.

The only disadvantage is that the address of this Qinhai Pharmaceutical Group is not in the province, but more than 2,000 kilometers away from the province.

But this is nothing, after all, the drugs produced by Changhua Pharmaceutical are sold to the whole country and even the world, not just to the province.

Therefore, the address of this pharmaceutical factory is not in the province, it doesn't matter, and there will be no inconvenience.

Moreover, if Changhua Pharmaceutical has a branch outside the province, the drugs produced can also be sold directly in other provinces without having to be transported back.

Because Liu's chain pharmacies are all over the country, no matter where the branch is in China, Liu's pharmacies will not be affected, and even some transportation costs and time can be saved, which is more convenient.

However, the scale of this Qinhai Pharmaceutical Group is higher than that of Xinjing Pharmaceutical Factory, so if you want to acquire Qinhai Pharmaceutical Group, the price is naturally not low.

At that time, Changhua Pharmaceutical acquired Xinjing Pharmaceutical Factory and used a loan of 2.5 billion yuan to acquire Xinjing Pharmaceutical Factory.

The Qinhai Pharmaceutical Group has expressed its intention to transfer, all the shareholders have said that they can sell the shares in their hands, and Li Changhua negotiated the price back with them, Changhua Pharmaceutical needs to pay 2.8 billion in cash to acquire all the shares of Qinhai Pharmaceutical Group, and it needs to bear 2 billion in debt.

In other words, if you want to acquire Qinhai Pharmaceutical Group, Changhua Pharmaceutical will need to pay 4.8 billion yuan to get all the shares.

The purchase price of Qinhai Pharmaceutical Group is almost twice as high as that of Xinjing Pharmaceutical Factory.

However, after investigation, the acquisition of Qinhai Pharmaceutical Group for 4.8 billion yuan is still worth this price.

If Qinhai Pharmaceutical Group can be acquired, after integration, the overall production capacity of Changhua Pharmaceutical can be increased by at least 50%.

Moreover, there is still a lot of room for improvement in the production capacity of Qinhai Pharmaceutical Group, and after the initial increase, the production capacity of Qinhai Pharmaceutical Group itself can be increased by another 30%.

Therefore, the acquisition of Qinhai Pharmaceutical Group is very helpful for Changhua Pharmaceutical to increase the production capacity of drugs.

This is also why Li Changhua will take a fancy to Qinhai Pharmaceutical Group and collect detailed information, so that Su Zhe can use it as a reference and make a decision.

At present, Changhua Pharmaceutical's cash reserves can also be acquired with 4.8 billion in cash.

It's just that if Changhua Pharmaceutical takes out 4.8 billion yuan in cash to acquire Qinhai Pharmaceutical Group, it will not be able to pay off the loan of 2.5 billion yuan from the bank because of the acquisition of Xinjing Pharmaceutical Factory.

Originally, Changhua Pharmaceutical planned to repay this loan within this month, but if it wanted to acquire Qinhai Pharmaceutical Group, it would not be possible.

Of course, if Changhua Pharmaceutical wants to acquire Qinhai Pharmaceutical Group, it does not need to take out 4 billion at one time, but can first take out 2.8 billion in cash to acquire the shareholders' shares, and as for the group's debts, they can be repaid slowly, which is not urgent.

It's just that Su Zhe doesn't want to make trouble in the future, and wants to solve all the debts of Qinhai Pharmaceutical Group at the same time as the acquisition, so as not to leave trouble in the future.

Therefore, if you want to acquire Qinhai Pharmaceutical Group, you need 4.8 billion yuan. (To be continued......)